Screener
Regenxbio RGNX Total Cost of Revenue
Discontinued — last reported Q4 '24
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Regenxbio’s 10-K, filed March 13, 2025.
- Filed
- Mar 13, 2025
- Fiscal year
- FY2024
- Accession
- 0000950170-25-038770
| Line item | Years Ended December 31, 2024 | Years Ended December 31, 2023 | Years Ended December 31, 2022 |
|---|---|---|---|
| License and royalty revenue | $83,328 | $90,242 | $112,724 |
| Total revenues | 83,328 | 90,242 | 112,724 |
| Operating Expenses | |||
| Cost of revenues | 33,567 | 37,213 | 54,545 |
| Research and development | 208,522 | 232,266 | 242,453 |
| General and administrative | 76,619 | 88,494 | 85,281 |
| Credit losses (recoveries) | (5,000) | — | — |
| Impairment of long-lived assets | 2,101 | — | — |
ITEM 16. FORM 10-K SUMMARY
FAQ
- What is Regenxbio's total cost of revenue?
- Regenxbio (RGNX) reported total cost of revenue of $6.32M in Q4 2024.
- How has Regenxbio's total cost of revenue changed year-over-year?
- Regenxbio's total cost of revenue decreased by 43.8% year-over-year, from $11.24M to $6.32M.
- What is the long-term trend for Regenxbio's total cost of revenue?
- Over 3 years (2021 to 2024), Regenxbio's total cost of revenue has grown at a -13.5% compound annual growth rate (CAGR), from $51.83M to $33.57M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Regenxbio's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude